argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025

August 19, 2025

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it will host a webinar, titled “R&D Spotlight | Pioneering MuSK Biology with ARGX-119” on Tuesday, September 16, 2025, at 2:00pm ET.

The webinar will be the first of a ‘mini’ series highlighting the argenx pipeline and research and development strategy. argenx management and scientific leadership will be joined by key opinion leaders, who will discuss the development of the MuSK agonist program, ARGX-119, and its potential to treat neuromuscular diseases, including congenital myasthenic syndromes (CMS), amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA).

A webcast of the event can be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.

Contacts

Media:

Colin McBean
cmcbean@argenx.com

Investors:

Alexandra Roy
aroy@argenx.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.